FDA Casts Wide Net For Advice on Avandia
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency increases number of voting members for the meeting of the Endocrinologic and Metabolic and Drug Safety and Risk Management Advisory Committees to 33, up 10 from 2007. Half of the committee's voting members also participated in the first review of rosiglitazone's postmarketing safety.